UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
May
13, 2008 (May 12, 2008)
______________
Introgen
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware |
0-21291 |
74-2704230 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
301 Congress Avenue, Suite 1850
Austin, Texas 78701
(Address
of principal executive offices, including zip code)
(512)
708-9310
(Registrant’s
telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On May 12, 2008, Introgen Therapeutics, Inc. issued a press release announcing its financial results for the three months ended March 31, 2008. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.
Item 9.01. Financial Statements and Exhibits.
| (d) |
Exhibits. |
|
| 99.1 | Press Release dated May 12, 2008. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
INTROGEN THERAPEUTICS, INC. |
|||
|
|
|
By: |
/s/ JAMES W. ALBRECHT, JR. |
|
|
James W. Albrecht, Jr. |
||||
|
Chief Financial Officer |
||||
|
Date: |
May 12, 2008 |
|||
EXHIBIT INDEX
|
Exhibit No. |
Description |
| 99.1 |
Press Release dated May 12, 2008. |